These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12385689)

  • 1. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes.
    Labana S; Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2002 Oct; 20(4):301-4. PubMed ID: 12385689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.
    Deol P; Khuller GK; Joshi K
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1211-4. PubMed ID: 9174172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
    Dutt M; Khuller GK
    J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs.
    Pandey R; Sharma S; Khuller GK
    Indian J Exp Biol; 2004 Jun; 42(6):562-6. PubMed ID: 15260105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
    Ahmad Z; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2005 Oct; 26(4):298-303. PubMed ID: 16154726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
    Ul-Ain Q; Sharma S; Khuller GK
    Antimicrob Agents Chemother; 2003 Sep; 47(9):3005-7. PubMed ID: 12937014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
    Dutt M; Khuller GK
    Antimicrob Agents Chemother; 2001 Jan; 45(1):363-6. PubMed ID: 11121000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects.
    Qurrat-ul-Ain ; Sharma S; Khuller GK; Garg SK
    J Antimicrob Chemother; 2003 Apr; 51(4):931-8. PubMed ID: 12654730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selected pharmaceutical excipient prevent isoniazid and rifampicin induced hepatotoxicity.
    Shih TY; Ho SC; Hsiong CH; Huang TY; Hu OY
    Curr Drug Metab; 2013 Jul; 14(6):720-8. PubMed ID: 23701163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomes and PLG microparticles as sustained release antitubercular drug carriers--an in vitro-in vivo study.
    Dutt M; Khuller GK
    Int J Antimicrob Agents; 2001 Sep; 18(3):245-52. PubMed ID: 11673037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual antitubercular drug loaded liposomes for macrophage targeting: development, characterisation,
    Shrivastava P; Gautam L; Sharma R; Dube D; Vyas S; Vyas SP
    J Microencapsul; 2021 Mar; 38(2):108-123. PubMed ID: 33267623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice.
    Deol P; Khuller GK
    Biochim Biophys Acta; 1997 Mar; 1334(2-3):161-72. PubMed ID: 9101710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India.
    Ranjalkar J; Mathew SK; Verghese VP; Bose A; Rose W; Gupta D; Fleming DH; Mathew BS
    Int J Antimicrob Agents; 2018 May; 51(5):663-669. PubMed ID: 29241821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 17. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis.
    Nyazema NZ; Rabvukwa P; Gumbo J; Ndudzo P; Chitemerere C
    Cent Afr J Med; 1999 Jun; 45(6):141-4. PubMed ID: 10695183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.